As of 2026-04-03, TScan Therapeutics Inc. (TCRX) trades at a current price of $1.01, marking a 1.94% decline in its most recent trading session. This analysis focuses on key technical levels, prevailing market context, and potential short-term scenarios for the clinical-stage biotech stock, with no recent earnings data available for the company at the time of publication. TCRX, which operates in the engineered T-cell receptor therapy space, has seen muted price action in recent weeks, trading wi
TCRX Stock Analysis: TScan Therapeutics Inc. Biotech at $1 Level Following Small Daily Dip
TCRX - Stock Analysis
3636 Comments
1759 Likes
1
Jamalyn
Community Member
2 hours ago
Missed out again… sigh.
👍 111
Reply
2
Azuree
Registered User
5 hours ago
I can’t help but think “what if”.
👍 254
Reply
3
Zyrihanna
Trusted Reader
1 day ago
Access real-time US stock market data with expert analysis and strategic recommendations focused on building a balanced and profitable portfolio. We help you diversify across sectors and industries to minimize concentration risk while maximizing growth potential.
👍 132
Reply
4
Dulcey
Active Contributor
1 day ago
The technical and fundamental points complement each other nicely.
👍 22
Reply
5
Telena
Legendary User
2 days ago
Expert US stock credit rating analysis and default risk assessment to identify financial distress signals and potential investment risks in your portfolio. We monitor credit markets to understand the health of companies and potential risks to equity holders from debt obligations. We provide credit ratings, default probabilities, and spread analysis for comprehensive credit risk assessment. Understand credit risk with our comprehensive credit analysis and default assessment tools for risk management.
👍 18
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.